Diagnostics
Filter News
Found 6,192 articles
-
CDx Diagnostics’ WATS3D Receives “Medically Necessary” Designation From Highmark Health Plans
11/17/2021
WATS3D, a diagnostic platform developed by CDx Diagnostics to empower physicians to detect Barrett’s esophagus (BE) and esophageal dysplasia, has been designated as medically necessary by Highmark Blue Cross Blue Shield plans in Delaware, Pennsylvania, and West Virginia.
-
Sense Announces Increase of Series B to $65 Million to Support Launch of Rapid, Point-of-Care Molecular Diagnostic
11/17/2021
Global molecular diagnostics innovator, Sense Biodetection, announced that after achieving several key milestones this year, the company’s Series B funding round has been increased to $65M, an additional $15 million from prior commitments.
-
Agilent Increases Cash Dividend to 21 Cents Per Share
11/17/2021
Agilent Technologies, Inc. announced the company has increased its quarterly dividend to 21 cents per share of common stock, reflecting an 8% increase over the previous quarter.
-
StageZero Life Sciences Announces Q3 2021 Financial Results
11/16/2021
StageZero Life Sciences, a vertically-integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, announced its third-quarter financial results for the three months ended September 30, 2021, and provided an update on its business progress.
-
Update: Todos Medical Reports Third Quarter 2021 Business and Financial Results
11/16/2021
Todos Medical, Ltd., a comprehensive medical diagnostics and related solutions company, announced financial results for the third quarter ended September 30, 2021.
-
Biovica’s DiviTum(R)TKa Results Published in Journal of Medical Economics
11/16/2021
Biovica, active in cancer diagnostics, announced that the results of a DiviTum®TKa budget impact model have been published in the Journal of Medical Economics.
-
Biofrontera Kicks Off US Clinical Study Program for Ameluz®
11/16/2021
Biofrontera Inc., a biopharmaceutical company specializing in the commercialization of dermatological products, announced the start of a clinical study program focused on optimizing and expanding the market positioning of its in-licensed FDA-approved prescription drug Ameluz® for photodynamic therapy in the United States.
-
Inagene Diagnostics Inc. and The Newly Institute partner to optimize treatment for Canadians living with pain and/or mental health conditions
11/16/2021
Canadian pharmacogenetic testing provider, Inagene Diagnostics Inc., has partnered with The Newly Institute, an advanced network of medically assisted psychotherapy clinics in Canada, specializing in outpatient programs for mental health, addiction and chronic pain.
-
Todos Medical Reports Third Quarter 2021 Business and Financial Results
11/16/2021
Todos Medical, Ltd., a comprehensive medical diagnostics and related solutions company, announced financial results for the third quarter ended September 30, 2021.
-
Mainz Biomed to Exhibit ColoAlert at MEDICA 2021, the World’s Largest Medical Trade Fair
11/15/2021
Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce that Company representatives will be attending MEDICA 2021 to showcase ColoAlert, its highly efficacious and easy-to-use diagnostic test for colorectal cancer.
-
Quotient Limited Provides Second Quarter Fiscal 2022 Results
11/15/2021
Quotient Limited, a commercial-stage diagnostics company, headquartered in Eysins, Switzerland, reported its financial results for the second quarter of fiscal year 2022 and filed the quarterly report on Form 10-Q.
-
HTG Molecular Diagnostics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 15, 2021
11/15/2021
HTG Molecular Diagnostics, Inc., a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced that, on November 9, 2021 the Compensation Committee of the HTG Board of Directors granted inducement stock option awards to purchase an aggregate of 80,000 shares of common stock and 30,000 restricted stock unit awards to two employees who have recently joined HTG.
-
Talis Biomedical Announces Third Quarter 2021 Financial Results and Business ProgressConference call and webcast today at 4:30pm Eastern/1:30pm Pacific
11/15/2021
Talis Biomedical Corporation, a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, reported financial results and business progress for the third quarter ended September 30, 2021.
-
CYduct Diagnostics, Inc. Announces the Appointment of Anthony L.G., PLLC as Corporate and Securities Counsel
11/15/2021
CYduct Diagnostics, Inc. is pleased to announce the retaining of Ms. Laura Anthony and the firm Anthony L.G., PLLC.
-
Talis Biomedical Announces Appointment of Brian Blaser as President, Chief Executive Officer and Director
11/15/2021
Talis Biomedical Corporation, a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, announced the appointment of Brian Blaser to President, Chief Executive Officer and Director.
-
Biocept Reports Third Quarter 2021 Financial Results
11/15/2021
Biocept, Inc., a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and nine months ended September 30, 2021 and provides a business update.
-
Co-Diagnostics, Inc. to Host Booth at MEDICA 2021 Trade Fair in Düsseldorf, Germany
11/15/2021
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth this week at the MEDICA 2021 trade fair in Düsseldorf, Germany from 15-18 November.
-
Veracyte Announces New Data on Immuno-Oncology Offerings Presented at SITC 2021
11/13/2021
Veracyte, Inc. announced that new data from three posters were presented at the Society for Immunotherapy of Cancer's 36th Annual Meeting, highlighting the company’s immuno-oncology offerings for biopharmaceutical and academic researchers.
-
Quotient Limited to Participate in the Jefferies London Healthcare Conference
11/12/2021
Quotient Limited, a commercial-stage diagnostics company, announced the management team will present at the Jefferies London Healthcare Conference on Tuesday, November 16, 2021 at 8:40am GMT.
-
Imaging Biometrics and St. Jude Children's Hospital Enter Agreement
11/11/2021
IQ-AI Limited, a developer of medical image processing platforms that have led to effective therapeutic strategies for brain tumor and other patients, and St. Jude Children's Hospital, have entered into a Data Use Agreement.